NRIX is trading at $24.90 (+4.40%) in pre-market as investors continue to react to the strategic collaboration with Roche announced on June 8, 2026.
- The agreement provides Nurix with a $700 million upfront payment and potential milestone payments totaling up to $2.3 billion.
- The partnership focuses on co-development and commercialization across hematology, immunology, and neurology.
- The stock previously gained 4.3% on June 29 as the market continued to digest the long-term value of the multi-billion dollar deal.